Nuvation Bio, Inc.

Nuvation Bio is a global biopharmaceutical company dedicated to developing innovative oncology therapies that address some of the most challenging forms of cancer. Focused on advancing precision medicine, the company combines scientific expertise with cutting-edge research to develop treatments that improve outcomes and make a meaningful difference in the lives of patients worldwide.

Its clinical pipeline includes targeted therapies for cancers driven by specific genetic mutations, including next-generation ROS1 inhibitors, brain-penetrant IDH1 inhibitors, and innovative drug-drug conjugate (DDC) programs. By advancing novel therapeutic approaches and leveraging precision oncology, Nuvation Bio aims to deliver transformative treatments for patients with significant unmet medical needs.

Founded by experienced biopharmaceutical leaders, Nuvation Bio operates globally with research and development teams across North America and Asia. Through a commitment to scientific innovation, rigorous clinical development, and patient-centered research, the company is working to bring the next generation of life-changing cancer therapies to patients around the world.